Biotech entity
Every one of those 1 sits in a single category, pharma. Anthony Kirby is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Emily Prideaux, all published on August 10, 2026.
Last mentioned: Aug 10, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Anthony Kirby is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Emily Prideaux, all published on August 10, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 8 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Emily Prideaux. Shared-story counts are live from our verified record — not editorial picks.
Hikma Pharmaceuticals’ H1 2026 results mark a turning point: injectables have stabilised, EBIT rose nearly 8%, and the company is increasing R&D and senior hires in H2. For biotech and pharma investors, the narrative is shifting from recovery to growth, with the injectables unit expected to drive top- and bottom-line expansion from 2027.
Source: Daily Political · Markets Daily
Emily Prideaux is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
